Expression Analysis® Expands Sequencing Services

Single-Lane Sequencing with Guaranteed Turn Times and Firm-Fixed Pricing

DURHAM, N.C.--(BUSINESS WIRE)-- Expression Analysis, a leading provider of genomic services for clinical trials and research, announced today that it has expanded its sequencing services to include single-lane sequencing with guaranteed turn-around-times and, firm fixed pricing. The new service will be offered on the Illumina GA II and will include the following applications: Shotgun Sequencing, ChIP Seq, mRNA Seq and small RNA Seq.

"We have seen significant demand for a program like this, mainly from individual researcher, only needing to sequence one or two specimens. We are filling a need but, most importantly, every project has access to our in-depth expertise in sequencing and bioinformatics,” stated Steve McPhail CEO and President of Expression Analysis. “Another very unique aspect of our single-Lane Sequencing Program (http://singlelane.expressionanalysis.com) is the Flow Cell Tracker. Clients will be able to login and track their specimen(s) throughout the sequencing process.”

The benefits of the program extend further than guaranteed turn-around and firm-fixed-pricing; clients will have the assurance their studies will be handled by a proven industry leader with an unmatched depth and breadth of genomic expertise.

About Expression Analysis, Inc.

Expression Analysis (www.ExpressionAnalysis.com) provides whole genome to focused set gene expression and genotyping assays along with DNA sequencings services, sequence enrichment technologies and bioinformatics support. Platforms utilized include Affymetrix GeneChip® and GeneTitan®, Applied Biosystems’ Taqman, Fluidigm’s Biomark and Access Array Systems, Illumina BeadChip® and Genome Analyzer, NanoString Technologies nCounter® Analysis System, RainDance Technologies RDT 1000 and, in the near future, the Pacific Biosciences™ PacBio RS. Expression Analysis offers solutions for challenging specimens such as whole blood and FFPE tissues, as well as nucleic acid isolation and data analysis services. Our quality system follows CLSI guidelines and our CLIA-registered laboratory supports GLP compliance.



CONTACT:

Expression Analysis, Inc.
Karen Michailo, Senior Director of Marketing
919-287-4277 (office)
919-349-3687 (mobile)

KEYWORDS:   United States  North America  North Carolina

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics

MEDIA:

Logo
 Logo

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.